- Home
- FHN vs ROIV Comparison
FHN vs ROIV Comparison
Compare FHN & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHN
- ROIV
- Stock Information
- Founded
- FHN 1864
- ROIV 2014
- Country
- FHN United States
- ROIV United Kingdom
- Employees
- FHN N/A
- ROIV N/A
- Industry
- FHN Major Banks
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- FHN Finance
- ROIV Health Care
- Exchange
- FHN Nasdaq
- ROIV Nasdaq
- Market Cap
- FHN 10.4B
- ROIV 8.4B
- IPO Year
- FHN N/A
- ROIV N/A
- Fundamental
- Price
- FHN $20.83
- ROIV $10.94
- Analyst Decision
- FHN Buy
- ROIV Strong Buy
- Analyst Count
- FHN 15
- ROIV 8
- Target Price
- FHN $20.70
- ROIV $17.93
- AVG Volume (30 Days)
- FHN 5.4M
- ROIV 5.3M
- Earning Date
- FHN 01-16-2025
- ROIV 02-11-2025
- Dividend Yield
- FHN 2.88%
- ROIV N/A
- EPS Growth
- FHN N/A
- ROIV N/A
- EPS
- FHN 1.37
- ROIV 5.89
- Revenue
- FHN $3,071,000,000.00
- ROIV $129,128,999.00
- Revenue This Year
- FHN N/A
- ROIV $15.98
- Revenue Next Year
- FHN $2.23
- ROIV N/A
- P/E Ratio
- FHN $15.18
- ROIV $1.86
- Revenue Growth
- FHN 0.03
- ROIV 145.68
- 52 Week Low
- FHN $12.95
- ROIV $9.69
- 52 Week High
- FHN $21.72
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- FHN 59.03
- ROIV 38.75
- Support Level
- FHN $19.80
- ROIV $10.42
- Resistance Level
- FHN $20.79
- ROIV $11.82
- Average True Range (ATR)
- FHN 0.46
- ROIV 0.35
- MACD
- FHN 0.01
- ROIV -0.11
- Stochastic Oscillator
- FHN 92.40
- ROIV 29.21
About FHN First Horizon Corporation
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The regional bank is responsible for roughly 65% of its revenue, while capital markets make a 25% contribution. The remainder is split between the firm's non-strategic (wind-down) and corporate operations. First Horizon concentrates on offering a variety of banking products mainly in its home state, where it has the second- largest deposit franchise with a 13% deposit market share.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.